Food and Drug Administration (FDA) in February 2021 and expects to be on the market by year end. A business of developing a Point of Care, Rapid Response Diagnostic Device for detecting and differentiating between Bacterial & Viral Infections using. The company filed a pre-submission package with the U.S. The National Institutes of Health (NIH) has recently ranked 12-15 Molecular Diagnostics in the top 5% of COVID-19 diagnostic companies and funded the construction of its beta prototypes earlier this year. (Ray Baldwin) EAST HAVEN, CT In an otherwise nondescript location on Panagrossi Circle, a team of biomedical. The company is now focused on early COVID-19 diagnosis. Carfora visited the 12-15 Molecular Diagnostics lab in East Haven. Salaries, reviews, and more - all posted by employees working at 12-15 MOLECULAR. Salaries, reviews, and more - all posted by employees working at 12-15 MOLECULAR DIAGNOSTICS. Using its breakthrough Graphene Carbon-Nanotube platform technology, Veralize, 12-15 Molecular Diagnostics has demonstrated its ability to detect at Point of Care (POC) virtually any pathogenic or carcinogenic material contained in many bodily fluids, e.g., saliva, blood, etc., with comparable sensitivity to RT-PCR - yet Veralize is substantively cheaper and faster than RT-PCR. See what employees say its like to work at 12-15 MOLECULAR DIAGNOSTICS. See what employees say its like to work at 12-15 MOLECULAR DIAGNOSTICS. Interested in making a $500,000 direct EB-5 investment? Listen to the discussion with the Executive Chairman of 12-15 Molecular Diagnostics, developers of rapid response diagnostic devices designed to detect COVID-19 and other viral or bacterial infections.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |